Skip to main content
Wuhan YZY Biopharma Co., Ltd. logo

Wuhan YZY Biopharma Co., Ltd. — Investor Relations & Filings

Ticker · 2496 ISIN · CNE1000063C4 HKEX Manufacturing
Open in API
Filings indexed 135 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2496

About Wuhan YZY Biopharma Co., Ltd.

https://www.yzybio.com

Wuhan YZY Biopharma Co., Ltd. is a biotechnology company dedicated to the research, development, and industrialization of bispecific antibody (BsAb)-based therapies. The company focuses on addressing significant unmet medical needs in oncology, including the treatment of cancer and severe cancer-associated complications (such as malignant ascites and pleural effusion). A secondary focus is age-related ophthalmologic diseases, developing treatments for conditions like wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME), exemplified by pipeline candidate Y400. The company also maintains a research area in preventive vaccines, including the recombinant SARS-CoV-2 subunit protein vaccine Y2019. The firm leverages its proprietary technology platform, holding 78 patents in related fields.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT DATA FROM TWO CLINICAL STUDIES OF M701 "CD3/EpCAM BISPECIFIC ANTIBODY" TO BE PRESENTED AT 2026 ASCO ANNUAL MEETING
Regulatory Filings Classification · 85% confidence The document is a voluntary corporate announcement made under the Hong Kong Listing Rules, providing business updates on clinical trial data for a bispecific antibody to be presented at the ASCO Annual Meeting. It contains no financial statements, no voting or board changes, no share issuance or dividend information, nor is it a formal report (annual, interim, or audit). It does not fit into specific categories like earnings release, M&A, or investor presentation. Therefore, it falls into the miscellaneous category of general regulatory announcements (RNS).
2026-05-22 English
CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR
Board/Management Information Classification · 90% confidence The document is a board announcement from Wuhan YZY Biopharma regarding the resignation of the employee representative supervisor and the appointment of a new one. It details changes to the company’s supervisory board composition and biographical information of the incoming supervisor. This clearly falls under Board/Management Information.
2026-05-15 English
VOLUNTARY ANNOUNCEMENT NDA FOR TREATMENT OF MA OF M701 WAS ACCEPTED BY THE NMPA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Wuhan YZY Biopharma Co., Ltd. regarding the acceptance of a New Drug Application (NDA) for M701 by the National Medical Products Administration (NMPA) of China. It provides detailed information about the drug, clinical trials, and business updates. The document is not a financial report, earnings release, or regulatory certification. It is a business update announcement related to drug development progress and regulatory acceptance, which does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it contains substantive content rather than just a notice of report availability. The document is best classified as a Regulatory Filings (RNS) type, which is the fallback for miscellaneous regulatory or business announcements that do not fit other categories.
2026-05-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing for an equity issuer listed on the Hong Kong Stock Exchange, detailing movements in authorized share capital, issued shares, treasury shares, and public float sufficiency confirmation. It includes detailed tables on share capital and share options but does not contain financial statements, earnings data, or management discussion. It is a regulatory compliance filing related to share capital and shareholding movements rather than a financial report or announcement of voting results. The document is not a report publication announcement since it contains substantive data. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories like share issue announcements or director dealings.
2026-05-06 English
VOLUNTARY ANNOUNCEMENT - TWO CLINICAL STUDY RESULTS OF M701 SELECTED FOR PRESENTATION AT THE 2026 ASCO ANNUAL MEETING
Regulatory Filings Classification · 82% confidence The document is a voluntary announcement to the Hong Kong Stock Exchange regarding clinical study results being selected for presentation at an academic conference. It contains no financial results, no dividends, no management changes, and is not an investor presentation, earnings release, or regulatory report with specific financial metrics. Therefore, it falls under the general regulatory announcements category as it does not fit any more specific filing type.
2026-04-23 English
2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information Classification · 95% confidence The document is a comprehensive Environmental, Social and Governance (ESG) Report for YZYBIO covering governance, environmental metrics, social initiatives, and stakeholder communications, compiled under HKEX ESG reporting rules. It is not an announcement or appendix but the full ESG performance report. Therefore, it falls under Environmental & Social Information (Code: SR).
2026-04-16 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.